prion disease which lack the diagnostic hall- As genetic analysis of the PrP gene has detected cases of prion disease which could not have been differentiated from other types of dementia on clinical grounds (because age at onset was late and the progression of dementia was slow and unremarkable), the question has been raised as to how many cases of sporadic atypical prion disease go undetected. Some such cases will inevitably be missed and a systematic search is impracticable. Because prion disease has an incidence of only 1 in 1 000 000, and Alzheimer type dementia has an incidence of, perhaps, 1 in 10 by extreme old age, a search for cases of prion disease by gene analysis or biochemical investigation in elderly demented patients who have none of the distinguishing features of prion disease (table 2) is unlikely to be worthwhile. On the other hand, Alzheimer's disease in people under 40 years of age is also so rare that the chance of a patient with very rapid, familial dementia of early middle age onset having prion disease may be as high as 10%.
As a definitive diagnosis of prion disease can only be made using modem laboratory techniques to detect the presence of PrPsc, it is clear that patients with prion disease must have received a different diagnosis in the past. Where large pedigrees of inherited prion disease have now been traced, it is possible to identify the obligate carriers of the PrP gene mutation in previous generations. While some of these gene carriers died prematurely of illnesses which were presumably unrelated to prion disease, there is documentary evidence for many of them from hospital notes, death certificates, or recorded place of death (for example, in an asylum) that they were demented at the time of death. Table 3 gives a brief indication of some of these diagnoses in a pedigree with a mutation in the PrP gene.67 Interestingly, early diagnoses tended to be non-specific and therefore essentially correct (though sometimes quaint). These gave way to diagnoses which were specific, confident (and fashionable) but which were actually incorrect, before they were finally replaced by the current diagnosis of prion disease. Data on the evolution of clinical diagnoses before death are more scarce because they require a full set of clinical notes. It is discernible, however, that a neurological diagnosis was often preceded by a psychodynamic interpretation, unresolved grief on the premature death of a parent sometimes being cited.
An increasingly appreciated feature of the neuropathology of prion disease in a proportion of cases is the accumulation of deposits of PrP- This brief review of prion disease should indicate that the core disease of CJD can be fairly readily diagnosed in life as a very rapidly progressive dementia with ataxia, myoclonus, and a characteristic electroencephalogram, and can be confirmed at post mortem examination by the presence of SE and, sometimes, PrP amyloid plaques. The more atypical forms, however, cannot be differentiated clinically from other forms of dementia and post mortem examination of the brain may not resolve the diagnosis without the use of immunohistological techniques. None the less prion disease is a distinct entity, all cases being related by the accumulation in brain of PrPsc. Searching for these cases broadens the observed phenotype of prion disease and the identification of inherited cases is important for genetic counselling. Understanding prion disease is also important in relation to the production of amyloid. The recent demonstration that ,B amyloid plaques occur in the brains of middle-aged monkeys which have been injected intracerebrally with brain material containing ,3 amyloid taken from a patient with Alzheimer's disease, but not in the brains of age-matched monkeys or those injected with brain which did not contain /3 amyloid,'5 suggests that there may be close similarities in the mechanism of production of PrP amyloid and /3 amyloid. Although prion disease and Alzheimer's disease differ in that the former is very rare and the latter is relatively common, they are both neurodegenerative diseases of mature onset; the ratio of familial to sporadic cases is about 1:8 for each disease; familial cases have a mean earlier age at onset than sporadic cases, and mutations in the precursor protein are found in a large proportion of familial cases of each disease. The observation that transmission cannot be achieved from cases of atypical prion dementia and that /3 amyloidosis may be transmissible experimentally serves to remove transmissibil-ity as a truly distinguishing feature of prion disease and allows us to perceive prion disease in a new light.
